𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib

✍ Scribed by Fabio P. S. Santos; Yesid Alvarado; Hagop Kantarjian; Dushyant Verma; Susan O'Brien; Gloria Mattiuzzi; Farhad Ravandi; Gautam Borthakur; Jorge Cortes

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
286 KB
Volume
117
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Significance of suboptimal response to i
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase
✍ Yesid Alvarado; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Gautam Borthakur πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 338 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: The European LeukemiaNet recommendations for chronic myeloid leukemia (CML) defined a group of patients with suboptimal response to imatinib. The significance of this response was not well defined. ## METHODS: The significance of having had a suboptimal response during

Dynamics and management of cytopenias as
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure
✍ Alfonso QuintΓ‘s-Cardama; Fabio Pires De Souza Santos; Hagop Kantarjian; Susan O' πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 160 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: The incidence, dynamics, and management of cytopenias were investigated in patients with chronic myeloid leukemia in chronic phase (CP CML) who received dasatinib therapy after imatinib failure. ## METHODS: Data were analyzed from 130 patients with CP CML who were trea

The significance of myelosuppression dur
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
✍ Thomas B. Sneed; Hagop M. Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rio πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression β‰₯ Grade 3, requiring interruption of thera